MEP41008A - Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis - Google Patents
Use of bradykinin-b2 receptor antagonists for treating osteoarthrosisInfo
- Publication number
- MEP41008A MEP41008A MEP-410/08A MEP41008A MEP41008A ME P41008 A MEP41008 A ME P41008A ME P41008 A MEP41008 A ME P41008A ME P41008 A MEP41008 A ME P41008A
- Authority
- ME
- Montenegro
- Prior art keywords
- bradykinin
- receptor antagonists
- diseases
- treating osteoarthrosis
- osteoarthrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/043—Kallidins; Bradykinins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Peptidi sa bradikinin-antagonističkim djelovanjem dolaze u obzir za proizvodnju ljekova za profilaksu i terapiju oboljenja, na čiji tok utiče pojačana aktivnost metaloproteinaze matrice.Tu spadaju oboljenja kao što su degenerativna oboljenja zglobova, primjera radi osteoartoza, spondiloza i atrofija hrskavice posle traume zgloba ili dugotrajne imobilizacije zgloba posle oštećenja meniskusa ili čašice koljena ili povrede ligamenata.Peptides with bradykinin-antagonistic activity are considered for the production of drugs for prophylaxis and treatment of diseases, the course of which is affected by increased matrix metalloproteinase activity. These include diseases such as degenerative joint diseases, for example osteoarthritis, spondylosis and cartilage atrophy immobilization of the joint after damage to the meniscus or cup of the knee or injury to the ligaments.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10304994A DE10304994A1 (en) | 2003-02-07 | 2003-02-07 | The use of antagonists of the bradykinin B2 receptor for the treatment of osteoarthrosis |
| PCT/EP2004/000550 WO2004069266A2 (en) | 2003-02-07 | 2004-01-23 | Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis |
| YUP-2005/0565A RS51029B (en) | 2003-02-07 | 2004-01-23 | Use of bradykinin-b2 receptor antagonists for treating oseoarthrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MEP41008A true MEP41008A (en) | 2011-02-10 |
Family
ID=32797325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-410/08A MEP41008A (en) | 2003-02-07 | 2004-01-23 | Use of bradykinin-b2 receptor antagonists for treating osteoarthrosis |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1594520B1 (en) |
| JP (1) | JP2006516980A (en) |
| KR (1) | KR20050105447A (en) |
| CN (1) | CN1317029C (en) |
| AR (1) | AR043036A1 (en) |
| AT (1) | ATE335500T1 (en) |
| AU (1) | AU2004210396A1 (en) |
| BR (1) | BRPI0407333A (en) |
| CA (1) | CA2514152C (en) |
| CO (1) | CO5690613A2 (en) |
| CY (1) | CY1105708T1 (en) |
| DE (2) | DE10304994A1 (en) |
| DK (1) | DK1594520T3 (en) |
| ES (1) | ES2268622T3 (en) |
| HK (1) | HK1085926A1 (en) |
| HR (1) | HRP20050701B1 (en) |
| IL (1) | IL169899A0 (en) |
| MA (1) | MA27618A1 (en) |
| ME (1) | MEP41008A (en) |
| MX (1) | MXPA05007310A (en) |
| MY (1) | MY135827A (en) |
| NO (1) | NO333903B1 (en) |
| NZ (1) | NZ541680A (en) |
| PE (1) | PE20040939A1 (en) |
| PL (1) | PL206412B1 (en) |
| PT (1) | PT1594520E (en) |
| RS (1) | RS51029B (en) |
| RU (1) | RU2329057C2 (en) |
| TW (1) | TW200505472A (en) |
| WO (1) | WO2004069266A2 (en) |
| ZA (1) | ZA200505177B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0710522D0 (en) * | 2007-06-01 | 2007-07-11 | Royal Veterinary College The | Drug delivery system comprising matrix metalloproteinase inhibitors |
| IT1391236B1 (en) * | 2008-07-11 | 2011-12-01 | St Luso Farm D'italia Spa | PHARMACEUTICAL COMPOSITIONS BASED ON ANTAGONISTS OF THE B2 KININE AND CORTICOSTEROID RECEPTOR AND THEIR USE |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE63490B1 (en) * | 1988-11-24 | 1995-05-03 | Hoechst Ag | Peptides having bradykinin antagonist action |
| MX9100717A (en) * | 1990-08-24 | 1992-04-01 | Syntex Inc | BRADIQUININE ANTAGONISTS |
| FR2751650B1 (en) * | 1996-07-24 | 1998-10-09 | Fournier Ind & Sante | NOVEL N-BENZENESULFONYL-L-PROLINE COMPOUNDS, METHOD OF PREPARATION AND THERAPEUTIC USE |
| CA2364178C (en) * | 2000-12-05 | 2006-01-10 | Yasuhiro Katsu | N-benzenesulfonyl l-proline compounds as bradykinin antagonists |
| EP1496835A4 (en) * | 2002-02-01 | 2006-10-18 | Omeros Corp | Compositions and methods for systemic inhibition of cartilage degradation |
-
2003
- 2003-02-07 DE DE10304994A patent/DE10304994A1/en not_active Withdrawn
-
2004
- 2004-01-13 PE PE2004000064A patent/PE20040939A1/en not_active Application Discontinuation
- 2004-01-23 WO PCT/EP2004/000550 patent/WO2004069266A2/en active IP Right Grant
- 2004-01-23 KR KR1020057014116A patent/KR20050105447A/en not_active Application Discontinuation
- 2004-01-23 PL PL376605A patent/PL206412B1/en unknown
- 2004-01-23 DK DK04704552T patent/DK1594520T3/en active
- 2004-01-23 JP JP2006501585A patent/JP2006516980A/en active Pending
- 2004-01-23 CA CA2514152A patent/CA2514152C/en not_active Expired - Fee Related
- 2004-01-23 AU AU2004210396A patent/AU2004210396A1/en not_active Abandoned
- 2004-01-23 CN CNB2004800034498A patent/CN1317029C/en not_active Expired - Fee Related
- 2004-01-23 ES ES04704552T patent/ES2268622T3/en not_active Expired - Lifetime
- 2004-01-23 BR BR0407333-9A patent/BRPI0407333A/en not_active IP Right Cessation
- 2004-01-23 DE DE502004001159T patent/DE502004001159D1/en not_active Expired - Lifetime
- 2004-01-23 AT AT04704552T patent/ATE335500T1/en active
- 2004-01-23 RU RU2005127862/15A patent/RU2329057C2/en not_active IP Right Cessation
- 2004-01-23 ME MEP-410/08A patent/MEP41008A/en unknown
- 2004-01-23 RS YUP-2005/0565A patent/RS51029B/en unknown
- 2004-01-23 EP EP04704552A patent/EP1594520B1/en not_active Expired - Lifetime
- 2004-01-23 PT PT04704552T patent/PT1594520E/en unknown
- 2004-01-23 NZ NZ541680A patent/NZ541680A/en not_active IP Right Cessation
- 2004-01-23 MX MXPA05007310A patent/MXPA05007310A/en active IP Right Grant
- 2004-02-05 TW TW093102562A patent/TW200505472A/en unknown
- 2004-02-05 AR ARP040100363A patent/AR043036A1/en unknown
- 2004-02-06 MY MYPI20040362A patent/MY135827A/en unknown
-
2005
- 2005-06-27 ZA ZA200505177A patent/ZA200505177B/en unknown
- 2005-07-26 IL IL169899A patent/IL169899A0/en unknown
- 2005-08-03 CO CO05076615A patent/CO5690613A2/en not_active Application Discontinuation
- 2005-08-04 HR HRP20050701AA patent/HRP20050701B1/en not_active IP Right Cessation
- 2005-08-05 MA MA28425A patent/MA27618A1/en unknown
- 2005-09-06 NO NO20054144A patent/NO333903B1/en not_active IP Right Cessation
-
2006
- 2006-05-25 HK HK06106009A patent/HK1085926A1/en not_active IP Right Cessation
- 2006-10-16 CY CY20061101482T patent/CY1105708T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200900211A1 (en) | SUBSTITUTED IMIDAZOLONE DERIVATIVES, THEIR RECEIVING AND APPLICATION | |
| CY1116800T1 (en) | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC ANTIBODIES | |
| BR0112756A (en) | Compound, pharmaceutical composition, methods for treating prostaglandin-mediated diseases, nasal congestion, allergic asthma, and allergic rhinitis, and use of a compound | |
| ATE477252T1 (en) | SUBSTITUTED DIAZEPANES AS ANTAGONISTS AT OREXIN RECEPTORS | |
| UA111579C2 (en) | Heterocyclic 2-Aminobenzo [d] Oxazole Derivatives, Pharmaceutical Composition Based on Them and Their Applications for Disease Treatment | |
| PA8493701A1 (en) | COMPOUNDS TO TREAT OBESITY | |
| BRPI0512274A (en) | aryl-substituted piperazine derivatives | |
| CY1109624T1 (en) | Substituted thiophene derivatives as glycogen receptor antagonists, preparations and therapeutic uses | |
| MA29088B1 (en) | INDAZOLE-CARBOXAMIDE COMPOUNDS. | |
| BRPI0613859A8 (en) | nitrocathecol derivatives, their use and preparation process, as well as pharmaceutical composition | |
| NO20092470L (en) | Substituted diazepan compounds as orexin receptor antagonists | |
| BR112012013431A8 (en) | compound, pharmaceutical composition and its use | |
| BRPI0411840A2 (en) | Method and apparatus for treating osteoarthritis, cartilage disease, defects and injuries to the human knee. | |
| BRPI0615145A2 (en) | xanthine derivatives as selective hm74a agonists | |
| BR112012014180A2 (en) | compound, pharmaceutical composition, use of the pharmaceutical composition, and method for treating a disease or disorder. | |
| DE602004012858D1 (en) | 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS | |
| BRPI0713443A2 (en) | PIPERAZINILY DERIVATIVES USEFUL IN THE TREATMENT OF MEDICAL DISEASES BY GPR38 RECEIVER, USE AND PHARMACEUTICAL COMPOSITION CONTAINING SUCH COMPOUNDS AND PREPARATION PROCESSES | |
| ATE384058T1 (en) | THIAZOLE DERIVATIVES | |
| BRPI0507120A (en) | compounds, process for the manufacture thereof, pharmaceutical compositions comprising them, method for treating and / or prophylaxis of diseases that are associated with cb1 receptor modulation and their use | |
| BRPI0411661A (en) | n-phenylpiperazine derivatives and methods of prophylaxis or treatment of 5ht 2c receptor-associated diseases | |
| EA200501595A1 (en) | AZABICYCLIC DERIVATIVES AS ANTAGONISTS OF MUSCARINE RECEPTOR | |
| BRPI0409454A (en) | compounds, process for their manufacture, pharmaceutical compositions comprising them, method for the treatment and / or prophylaxis of diseases that are associated with the glucagon receptor and their use | |
| BRPI0608437A2 (en) | fused thiazole derivatives that have histamine h3 receptor affinity | |
| ATE495164T1 (en) | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| DE69922528D1 (en) | N-IMIDAZOLYL-ALKYL SUBSTITUTED CYCLIC AMINES AS HISTAMINE-H3 AGONISTS OR ANTAGONISTS |